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SUMMARY
Functional dyspepsia represents a heterogeneous group of gastrointesti-
nal disorders marked by the presence of upper abdominal pain or dis-
comfort. Although its precise definition has evolved over the last
several decades, this disorder remains shrouded in controversy. The
symptoms of functional dyspepsia may overlap with those of other
functional bowel disorders including irritable bowel syndrome and non-
erosive reflux disease.
There may be coexistent psychological distress or disease complica-
ting its presentation and response to therapy. Given the prevalence and
chronicity of functional dyspepsia, it remains a great burden to society.
Suspected physiological mechanisms underlying functional dyspepsia
include altered motility, altered visceral sensation, inflammation, ner-
vous system dysregulation and psychological distress. Yet the exact
pathophysiological mechanisms that cause symptoms in an individual
patient remain difficult to delineate. Numerous treatment modalities
have been employed including dietary modifications, pharmacological
agents directed at various targets within the gastrointestinal tract and
central nervous system, psychological therapies and more recently,
complementary and alternative treatments.
Unfortunately, to date, all of these therapies have yielded only margi-
nal results. A variety of emerging therapies are being developed for
functional dyspepsia. Most of these therapies are intended to normalize
pain perception and gastrointestinal motor and reflex function in this
group of patients.
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INTRODUCTION
Although the precise definition of dyspepsia remains
debatable, the most widely quoted definition is a chro-
nic, recurrent pain or discomfort centred in the upper
abdomen.1 The word ‘centred’ is further defined as being
mainly in or around the midline. Once an evaluation
has been performed and organic aetiologies for the dys-
peptic symptoms have been excluded, an affected
patient is said to be suffering from functional dyspepsia
(FD; previously termed non-ulcer dyspepsia).2 FD has
been defined by the Rome II international working
group as ‘at least 12 weeks, which need not be consecu-
tive, within the preceding 12 months of: (i) persistent or
recurrent dyspepsia (pain or discomfort centred in the
upper abdomen), (ii) no evidence of organic disease
(including at upper endoscopy) that is likely to explain
the symptoms and (iii) no evidence that dyspepsia is
exclusively relieved by defecation or associated with
the onset of a change in stool frequency or stool form’
[i.e. not irritable bowel syndrome (IBS)].3
Epidemiological studies suggest that approximately
15% of the general population in western countries
suffers with FD.4, 5 The association between female
gender and FD is not as clear-cut as in IBS.6 FD is
commonly diagnosed by gastroenterologists and
increasingly, in the age of ‘open-access’ endoscopy, by
primary care doctors.7, 8 Nearly two-thirds of dyspeptic
patients will eventually end up with a diagnosis of FD
following an evaluation.2 FD tends to be a chronic
condition with long-term studies demonstrating per-
sistent symptoms in >80% of affected patients after
6–7 years of follow-up.9, 10
Adding to the complexity of FD is the overlap in
symptoms with other common gastrointestinal (GI)
disorders, such as IBS and gastro-oesophageal reflux
disease (GERD). Studies have found that up to half of
patients with FD also suffer with IBS11 and a number
of epidemiological and pathophysiological similarities
have been shown to exist between the two condi-
tions.12 There is also evidence to suggest significant
overlap between GERD, particularly non-erosive reflux
disease, and FD.13 Further, psychological distress
appears to coexist more commonly in those with FD
compared with the general population.14 Interestingly,
a recent study found that psychological distress was
no more likely in those with functional vs. organic
causes of dyspepsia15 and, perhaps more importantly,
the severity of psychological distress correlated poorly
with the severity of the dyspeptic symptoms in FD.16
Related to how commonly FD occurs, its tendency
towards chronicity and frequent overlap with other
common conditions, it should come as no surprise that
the associated socioeconomic impact is profound. In
the US, it has been estimated that FD accounts for bil-
lions of dollars in direct and indirect costs.17 Other
studies have consistently found that FD negatively
affects quality of life.18–20
CLINICAL PRESENTATION
In addition to abdominal pain or discomfort, the FD
symptom complex may include a variety of other
symptoms including postprandial abdominal fullness,
bloating, early satiety, nausea, retching, vomiting, or
belching.21 Any combination of these symptoms may
intermittently occur over time.5, 9 Subtyping dyspep-
sia has been suggested, initially for research purposes;
however, over time, this practice has gained popular-
ity in clinical practice.22 The Rome II working group
has suggested a subtyping scheme based on the pre-
dominant or most bothersome single symptom. Ulcer-
like dyspepsia if the predominant symptom is that of
pain centred in the upper abdomen. Dysmotility-like
dyspepsia if the predominant symptom is a discom-
fort other than pain centred in the upper abdomen.
This discomfort may be described as or associated
with an upper abdominal fullness, early satiety, bloat-
ing, belching or nausea. Unspecified (non-specific)
dyspepsia if the predominant symptom fails to meet
one of two previous descriptions. Reflux-like dyspep-
sia is not included as this is believed to be a variant
of GERD.1 At present, it must be stated that there
is little evidence to support the notion that such sub-
typing offers insight into the underlying pathophysi-
ology or response to specific treatments in FD
patients.23–25 Time will tell to what extent such sub-
typing will be endorsed by the upcoming Rome III
criteria for FD.
PATHOPHYSIOLOGICAL MECHANISMS
A wide variety of pathophysiological mechanisms
have been postulated to contribute to the development
of symptoms in patients with FD (Figure 1). Of the
abnormalities proposed, alterations in gastroduodenal
motor and reflex function have been most extensively
studied. Delayed gastric emptying has been reported in
30–40% of FD patients.26–31 More recently, a small
study involving patients referred to the Mayo Clinic in
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Rochester, MN found that accelerated gastric emptying
was identified as commonly as delayed gastric empty-
ing in FD patients.32 These provocative findings
require validation at other centres. Further, as is the
case with delayed emptying, whether accelerated gas-
tric emptying is responsible for specific symptoms
remains poorly validated. A number of small studies
have demonstrated impaired accommodation of the
proximal stomach to a meal in approximately 40% of
FD patients.24, 33–35 Although there is some evidence
to suggest a correlation between abnormal accommo-
dation and specific symptoms, this has not been
confirmed by other studies.36, 37 In addition to altera-
tions in gastric emptying and accommodation, other
abnormalities in gastroduodenal physiology have been
reported including gastric antral hypomotility,38
abnormal gastric myoelectrical activity,39 small bowel
hypermotility with increased duodenal retrograde con-
tractions40 and unsuppressed postprandial phasic con-
tractility of the proximal small bowel.41 At present, it
remains unclear if any one or more likely, some com-
bination of these abnormalities is responsible for
symptoms in FD patients. For the field to move
forward, investigators will need to carefully consider
how these abnormalities interact with one another to
affect the overall function of the upper GI tract and
hopefully, symptoms.
Numerous studies have demonstrated the presence
of altered visceral perception in FD. Between 34% and
66% of FD patients have evidence of heightened sensi-
tivity to gastric balloon distention. Unfortunately, the
significance of this physiological finding remains
unclear as the presence of heightened perception of
gastric balloon distention has not been consistently
found to correlate with dyspeptic symptoms.34, 42–44
There is evidence to suggests that duodenal hypersen-
sitivity to lipids45, 46 and gastric acid47 also occur
more commonly in FD. Such findings likely have rele-
vance to a patient’s frequent association of dyspeptic
symptoms to eating a meal. The recent application of
sophisticated brain imaging techniques is improving
our understanding of the cortical sites responsible for
the processing of painful and non-painful sensations
arising from the stomach.48, 49 Going forward, such
information should prove useful both to better under-
stand the pain pathways responsible for symptom
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A role for inflammation in the pathogenesis of FD
has been postulated. So-called ‘post-infectious’ FD has
been documented after acute enteric infection50 and
may occur by several mechanisms including defective
resolution of inflammation, alterations in mucosal
function, changes in the enteric nervous system and
altered visceral sensation.51 It has been estimated that
previous enteric infection may play a role in the
development of as many as a one-fifth of FD cases.52
Similar reasoning has been postulated for Helicobacter
pylori’s role in FD, although such an association
remains somewhat controversial.53 Further, a study by
Hall et al. found increased gastric mucosal mast cells
in patients with and without H. pylori-associated FD.
They went on to suggest that these findings might
contribute to FD by altering signalling in the brain-
gut axis.54
Altered vagal activity has been observed in FD
suggesting an aetiological role for autonomic dys-
function.55, 56 In addition, psychological factors, such
as stress and neuroticism, and their effects on cen-
tral nervous function has been postulated as an
underlying mechanism for the symptoms in FD.57 A
recent study found that experimentally induced
anxiety (visual and auditory cues) can alter gastric
sensorimotor function in healthy subjects.58 This
suggests that psychological factors can alter physio-
logical function which may underlie some of the
symptoms of FD.
DIAGNOSTIC TESTING
By definition, patients with FD should have no organic
explanation for their symptoms. From a practical
Table 1. Traditional pharmacological treatment strategies for functional dyspepsia
Therapeutic intervention Efficacy Evidence
Helicobacter pylori eradication 36% responding with treatment vs.
30% with placebo. NNT of 18
Meta-analysis of 13 RCTs totalling 3186
patients
Previous meta-analyses and individual
RCTs with discordant results
Proton pump inhibitors 33% responding with treatment vs.
23% with placebo. NNT of 9






Twice as likely as placebo to improve
symptoms. NNT of 4 (assuming
placebo response of 41%)
Meta-analysis of 14 RCTs totalling 1053
patients
Efficacy may be overestimated due to pub-
lication bias and removal of cisapride
from the market
Histamine-receptor antagonists Benefit over placebo only in the
treatment of epigastric pain and
postprandial fullness
Meta-analysis of 11 RCTs totalling 2164
patients





73% responding with TCA,
desipramine, vs. 49% with placebo
by PP analysis. NNT of 4.
Relative risk of remaining
symptomatic of 0.55 with use of
either agent vs. placebo in meta-
analysis
Single RCT only demonstrating efficacy by
PP analysis and not ITT analysis
Meta-analysis of 4 RCTs totalling 153
patients
Antacids No better than placebo Only 1 RCT meeting criteria totalling 109
patients
Bismuth salts No better than placebo Meta-analysis of 5 RCTs totalling 311
patients
Sucralfate No better than placebo Meta-analysis of 2 RCTs totalling 246
patients
NNT, number needed to treat; RCT, randomized-controlled trials; PP, per-protocol; ITT, intention-to-treat; TCA, tricyclic anti-
depressant.
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Table 3. Prokinetic agents122










Increases gastric antral motility





















Mosapride Serotonin type 4 (5-HT4)-receptor
agonist




Increases gastric antral motility
Tegaserod Partial serotonin type 4 (5-HT4)
-receptor agonist
Accelerates gastric emptying
Increases gastric antral motility
Increases gastric fundic
accommodation
Table 2. Non-pharmacological treatment strategies for functional dyspepsia
Therapeutic intervention Efficacy Evidence
Dietary modification
Smaller, more frequent meals
Low fat
Avoidance of late evening meals










Improvement in some symptoms,
such as bloating, epigastric pain
and nausea as well quality of life
measures
Reductions in need for
antidepressant medications and
consultative services
Individual trials suggest clinical benefit







Reported improvement in 60–95%
with treatment vs. 30–55% with
placebo
Meta-analysis of 17 RCTs. However, results
difficult to interpret due to significant
methodological flaws. Agent purity and
long-term safety unproven
RCT, randomized-controlled trial.
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(1) Placebo-controlled trial in which mosapride no better than placebo
(2) Trial in which mosapride demonstrated benefit but less than that of famotidine
(3) Trial in which mosapride equivalent to famotidine
Tegaserod Phase II trial demonstrating superiority to placebo in normalization of gastric emptying in
FD
Phase III trials underway
Itopride Phase II trial demonstrating superiority to placebo in the treatment of global symptoms in
FD
Failed to show efficacy in European phase III trial
Levosulpiride Single trial demonstrating efficacy equal to cisapride in relieving symptoms of
dysmotility-like FD
j-Opioid receptor
Fedotozine More effective than placebo in relieving dyspeptic symptoms in a preliminary multicentre
trial
Preliminary results not reproduced in a follow-up (unpublished) trial and drug develop-
ment halted
Asimadoline Decreased postprandial fullness and satiation in a randomized, double-blind,
placebo-controlled trial involving 39 healthy adults
Serotonergic
Sumatriptan Induced fundic relaxation and increased perception threshold in healthy volunteers
Failed to relieve postprandial symptoms in FD patients with impaired gastric
accommodation
Alosetron Superiority to that of placebo (54% vs. 43%) in relieving dyspeptic symptoms in women
with FD in a dose ranging study
Afferent nervous system receptor





Receptor antagonism reduced visceral pain response to distention in mouse model;








Receptors found in the gastric mucosa and muscle of animal models
Conflicting results with capsaicin compared to placebo in two trials
Sodium-channel receptor
agents




Several small studies demonstrating the ability of octreotide to reduce the sensation of





Loxiglumide shown in an open trial to control the dyspeptic symptoms produced by a
CCK analogue
Dexloxiglumide shown in double-blinded, placebo-controlled trial to prevent dyspeptic





Multicentre, placebo-controlled trial in which aprepitant demonstrated efficacy in
treatment of chemotherapy-induced vomiting




Preclinical animal studies suggesting a role of CRF antagonists in preventing
stress-induced gastric dysmotility
FD, functional dyspepsia; NMDA, N-methyl-D-aspartate; CCK, cholecystokinin.
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standpoint, this means that a symptomatic patient
should have no evidence of structural disease by upper
endoscopy or barium radiography to qualify for the
diagnosis of FD. The separation of patients with dys-
pepsia by the presence or the absence of visible struc-
tural disease is reasonably reliable. However, it is
important to remember that there is evidence to sug-
gests that a subgroup of those initially diagnosed with
FD are at-risk for the subsequent development of
peptic ulcer disease.59 Most agree that patients with
symptom onset over the age of 50–55 years or the
presence of ‘alarm features’, such as dysphagia, vomit-
ing, weight loss, anaemia or GI bleeding, should
undergo structural evaluation with endoscopy. A recent
evaluation from the CORI database found that dyspep-
sia served as the indication for 43% of over 117 000
upper endoscopic procedures.60 Thirty-six percentage
of dyspeptic patients were under the age of 50 years
and had no alarm features. Gastric malignancy was
found in 0.3% and was associated with increasing age,
male sex, Asian or Native American race, and alarm
features including weight loss and vomiting. Peptic
ulcer disease and oesophageal inflammation were iden-
tified in 5% and 16% respectively. A recent meta-ana-
lysis found that the negative predictive value of having
any alarm feature was excellent (99%), but the positive
predictive value of alarm features was poor (6%).61
These findings confirm what most clinicians already
know: the absence of alarm symptoms makes the likeli-
hood of finding important structural causes for dyspep-
sia very unlikely, but the vast majority of patients with
alarm symptoms will have no significant structural
explanation for their symptoms on upper endoscopy.
The Rome II definition for FD has been criticized for
being vague and of limited utility in clinical practice.
As has already been discussed, attempts to use symp-
tom clusters to identify subgroups of patients with spe-
cific physiological abnormalities, such as abnormal
gastric emptying and/or accommodation have met with
limited success. For the most part, symptoms and phy-
siological abnormalities correlate poorly in patients
with FD. There is some evidence to suggest that post-
prandial fullness, nausea and vomiting are reported
more commonly in patients with abnormal gastric
emptying of solids, whereas early satiety and weight
loss are more commonly reported by patients with
impaired gastric accommodation.36 Unfortunately
though, these symptoms occurred more commonly in
patients with delayed gastric emptying and/or abnor-
mal accommodation but there was considerable overlap
in symptoms between those with and without these
abnormalities. Perhaps most importantly, to date, the
identification of functional abnormalities has not
clearly translated to improved outcomes in response to
specific therapies. Related to these points, the clinical
utility of detailed testing to identify physiological
abnormalities in gastric emptying (scintigraphy,
octanoate breath testing), accommodation (barostat,
Single photon emission computed tomography, Ultra-
sound, nutrient drink test) and gastric electrical rhyth-
micity (electrogastrography) remains to be determined.
CURRENT TREATMENT OPTIONS
A wide variety of treatments have been used to man-
age FD including dietary and lifestyle modifications,
H. pylori eradication, antacids, mucosal protectants,
antisecretory agents, prokinetics, antidepressants,
behavioural therapies as well as complementary and
alternative medical (CAM) therapies (Tables 1 and 2).
The fact that no single available therapy consistently
provides relief to the majority of FD patients validates
the heterogeneity of this disorder. Given this hetero-
geneity, it is difficult to generalize about the charac-
teristics, which predict a greater or lesser response to
therapy for this condition. Acknowledging this point,
several authors have tried to identify predictors of
response to therapy. A recent systematic review repor-
ted several characteristics of FD patients that negat-
ively affect symptom remission including symptom
duration exceeding 2 years, lower educational level,
greater psychological vulnerability, coexistent H. py-
lori infection, use of aspirin, history of peptic ulcer
disease and treatment for GERD.5 An earlier review of
the literature reported limited evidence to suggest that
older age, male sex, single marital status and more
frequent occurrence of abdominal pain had a negative
Table 5. Rome III diagnostic criteria: functional
dyspepsia.150





(ii) No evidence of structural disease that is likely
to explain symptoms (including upper endoscopy)
(iii) Criteria fulfilled for the last 3 months with symptom
onset at least 6 months before diagnosis
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impact on the prognosis of FD, although these findings
are more controversial.62 Recent evidence suggests
that patients with overlapping FD and IBS report more
severe symptoms and are more likely to exhibit vis-
ceral hypersensitivity in response to gastric disten-
tion.11 Another recent study found that patients with
overlapping GERD symptoms and IBS reported more
severe heartburn than those with GERD symptoms
alone.63 These finding suggest that patients with mul-
tiple GI symptoms may represent a distinct subgroup
with more severe symptoms, perhaps related to a more
generalized disorder of altered visceral pain sensation.
It is attractive to hypothesize that such patients may
be more likely to respond to centrally acting therapies
and less likely to respond to peripherally acting agents
though this remains to be proven in clinical trials.
Dietary modifications
There are no trials which have formally evaluated the
efficacy of various dietary or lifestyle modifications in
patients with FD. Such treatment approaches have
evolved from the observation that the symptoms of FD
are frequently temporally related to the ingestion of
food. A recent systematic review on this topic conclu-
ded that although a relationship between the ingestion
of food and dyspeptic symptoms is frequently reported
by FD patients, this relationship has not been formally
assessed in careful clinical trials.64 This review repor-
ted that factors, such as food intolerances and eating
patterns have only been anecdotally reported to play a
role in the symptoms of FD. However, there is some,
albeit limited, evidence that dietary fat ingestion is
associated with dyspeptic symptoms.45, 65 Despite the
lack of evidence, modifications similar to those recom-
mended for GERD can be considered including smaller,
more frequent meals; a low fat diet and avoidance of
late evening meals. A food diary may be used to faci-
litate the identification of specific foods that trigger
symptoms. Foods frequently reported to worsen dys-
peptic symptoms include onions, peppers, citrus fruit,
coffee, carbonated beverages and spices. Though not
evidence-based, these recommendations are not associ-
ated with significant costs and unlikely to be associ-
ated with adverse outcomes.
H. pylori eradication
The role of H. pylori eradication in the treatment of
FD remains controversial. Two recent trials concluded
that H. pylori eradication improved quality of life66
and provided symptomatic benefit in FD.67 This is in
contrast to other contemporary studies demonstrating
no clear benefit compared with placebo or antisecre-
tory agents.68–71 A recent analysis of two multicentre,
multinational randomized-controlled trials (RCT)
revealed no benefit to H. pylori eradication over pla-
cebo although a subgroup analysis revealed a signifi-
cant benefit in reflux-like and ulcer-like dyspepsia as
well as a benefit in those with healing of gastritis.72
In an effort to clarify the ambiguity that exists
amongst clinical trials, several meta-analyses have
been published also revealing discordant results.73–77
Three analyses concluded that a small yet statistically
significant benefit existed with H. pylori eradication
over placebo.73, 76, 77 One analysis revealed that no
benefit existed74 and one revealed that insufficient
evidence existed to make a determination.75 Further
evaluation of these meta-analyses determined that
only 11–38% of dyspeptics were symptom-free as a
result of H. pylori eradication.78 The most recent
update of the Cochrane database reported a small but
statistically significant symptomatic benefit to curing
H. pylori in patients with FD [H. pylori cure ¼ 36%
vs. placebo ¼ 30%, relative risk reduction: 8%; 95%
CI: 3–12%, number needed to treat (NNT) ¼ 18].79 At
present, it is reasonable to conclude that on a popula-
tion basis, there appears to be a small but statistically
significant benefit to H. pylori eradication in FD
although the factors predicting a treatment response
remain largely unknown.80 On a practical level, the
clinician should understand that the prevalence of H.
pylori is dropping or already low in many parts of the
world and even when the organism is identified, the
likelihood of achieving symptom improvement in FD
patients following eradication therapy is likely to be
<50%.
Antacids
Antacids have been evaluated in a small number of
trials and consistently found to be no better than pla-
cebo in the treatment of FD.81–83 The Cochrane Colla-
boration reported that only the trial by Gotthard
et al.81 met methodological criteria for inclusion in
their review on the pharmacological interventions for
FD.84 This trial assessed the effects of antacids on epi-
gastric pain, bloating and nausea, only demonstrating
marginal improvement in the symptom of bloating
with antacids over that of placebo. A systematic
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review by Moayyedi et al. also concluded that antacids
were not significantly superior to placebo.85
Bismuth
The Cochrane review identified a total of nine RCTs
comparing the efficacy of bismuth to placebo.84 From
these studies, five trials were included in a meta-ana-
lysis totalling 311 patients.85 Significant heterogeneity
was noted and these trials tended to include patients
with H. pylori infection. This analysis revealed that
bismuth was no more effective than placebo though
there was a trend towards improvement that favoured
bismuth. Given concerns regarding accumulation and
associated toxicity, bismuth should be reserved for the
treatment of infrequent dyspeptic symptoms.
Sucralfate
Sucralfate has been studied in a limited number of
clinical trials and found to be no more effective than
placebo in the treatment of FD. A Cochrane review
identified three RCTs in which sucralfate was com-
pared with placebo in FD.84 Two of these trials were
included in a meta-analysis (246 patients) which
demonstrated no benefit of sucralfate over placebo
for FD.
Histamine-receptor antagonists
Though the histamine-receptor antagonists (H2RAs) are
commonly used to treat FD, the evidence supporting
their efficacy is modest at best. Available studies sug-
gest that their benefits may be limited to the symptom
of epigastric pain. A meta-analysis performed by Red-
stone et al. which included 22 RCTs reported superior-
ity of the H2RAs over placebo for improvement and
complete resolution of epigastric pain but not global
symptoms in FD patients.86 More recently, an analysis
of 11 RCTs performed by Moayyedi et al. involving
2164 patients concluded that overall improvement in
dyspepsia was significantly greater with H2RAs com-
pared to placebo.85 The investigators noted that signi-
ficant heterogeneity existed amongst the studies. They
also pointed out that the benefit of the H2RAs over
placebo may have been inflated by the poor methodo-
logical quality of the studies included. This possibility
was reiterated by another recent publication addres-
sing the methodological quality of treatment trials for
FD.87
Proton pump inhibitors
Proton pump inhibitors (PPIs) have been evaluated in
a number of large, well-designed RCTs. Based on the
results of a meta-analysis, including eight studies and
3293 treated patients, PPI therapy given for 2–8 weeks
was more effective in relieving or eliminating symp-
toms than placebo in patients with FD (33% and 23%
response rates with PPI and placebo, respectively; rel-
ative risk of remaining symptomatic ¼ 0.86, 95% CI:
0.78–0.95; NNT ¼ 9).88 Though there was significant
heterogeneity amongst the included trials, no asym-
metry was found on a funnel plot decreasing concerns
about publication bias. The risk ratio for remaining
dyspeptic was similar between standard- and low-dose
PPI regimens. Furthermore, patients with reflux-like
symptoms and symptoms described with the words
‘burning’ or ‘sour’ are more likely to improve with PPI
therapy. On the other hand, patients with symptoms
suggestive of dysmotility, such as nausea and bloating
are less likely to respond to PPIs.89 Additionally, the
cost-effectiveness of PPI therapy for FD varies widely
among different countries and is highly dependent
upon the local cost of PPI therapy and whether ther-
apy needs to be given continuously or only intermit-
tently to control symptoms.80
Prokinetics
The term prokinetic refers to a diverse group of medi-
cations that share the common characteristic of accel-
erating GI motility. Broadly speaking, these drugs
exert their physiological actions through effects on a
variety of neurotransmitter receptors including acetyl-
choline, dopamine, motilin and serotonin. Some exam-
ples of prokinetic drugs and their proposed mechanism
of actions can be found in Table 3.
A fundamental question regarding the prokinetics is
the mechanism/s by which they benefit symptoms. As
has been mentioned, the relationship between acceler-
ating gastric emptying and symptom improvement is
tenuous. This point is perhaps best illustrated by the
motilin receptor agonists, erythromycin and ABT-229.
While these agents clearly accelerate gastric emptying,
they often have little effect on and sometimes can
actually worsen symptoms, particularly at higher
doses.90, 91 It has been proposed that this disconnect
may in part be related to the deleterious effects of
these drugs on accommodation.90, 91 At present, it is
safe to conclude that different classes of prokinetic
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agents benefit symptoms by mechanisms which may
include but clearly extend beyond their effects on gas-
tric emptying.
A recent systematic review reported that as a
class, prokinetics appear to be more effective than
placebo in the treatment of FD.84 Fourteen RCTs
totalling 1053 patients were pooled demonstrating
that prokinetics were twice as likely as placebo to
improve dyspeptic symptoms. However, caution
should be exercised in the interpretation of these
results as the majority of the RCTs evaluated cisa-
pride (a mixed 5-HT4 agonist and 5-HT3 antagonist
that is no longer commercially available), the quality
of many of these studies was marginal, heterogeneity
existed amongst the included studies and a funnel
plot suggested that publication bias may have influ-
enced the results. Another meta-analysis pooling the
results of 17 studies evaluating cisapride and four
studies evaluating the dopaminergic antagonist, dom-
peridone (not licensed in the US) revealed a margi-
nal benefit compared with placebo based on the
investigator’s or patient’s assessment of global symp-
toms.92 A more recent meta-analysis demonstrated
that the observed benefit of prokinetics over placebo
was lost when an the analysis was restricted to high
quality studies.87
At present, the greatest activity appears to be
focused on the development of serotonergic and dop-
aminergic drugs. Conflicting data currently exists on
the efficacy of the mixed 5-HT4 agonist and 5-HT3
antagonist, mosapride.93–95 Tegaserod is a 5-HT4-
receptor agonist that is currently approved for the
treatment of women with the IBS and constipation
and men and woman under the age of 65 years with
chronic constipation. Tegaserod has been preliminarily
shown to accelerate gastric emptying of solids in
patients with FD and delayed gastric emptying.96–98 In
a phase II RCT evaluating patients with FD, a dose of
6 mg t.d.s. normalized gastric emptying in 80% vs.
50% for placebo (P < 0.058).98 In a recent small trial,
tegaserod 6 mg b.d. improved gastric accommodation
after eating a meal in functional dyspeptics with nor-
mal gastric emptying.96 Phase III trials evaluating te-
gaserod in patients with FD are currently nearing
completion in North America.
In a randomized trial, the dopaminergic antagonist,
levosulpiride was as effective as cisapride in relieving
symptoms in patients with dysmotility-like FD.99 Like
another dopaminergic antagonist, domperidone, levo-
sulpiride can be associated with breast tenderness and
galactorrhea. This drug is available in some parts of the
world but is currently not available in the US. A recent
high quality phase II trial randomized 554 patients with
FD to placebo or one of three doses of itopride, a dop-
aminergic antagonist with weak muscarinic agonist
activity. Itopride significantly improved global dyspep-
tic symptoms and composite symptom score using the
Leeds Dyspepsia Questionnaire. Overall, this drug was
safe and well tolerated.100 However, a recent European
phase III trial with itopride failed to meet its primary
end point in confirming efficacy in the treatment of FD.
A phase III trial in North America is currently ongoing
with results pending. Further data analysis and the
results of this ongoing trial should clarify what role ito-
pride may play in patients with FD.
Antidepressants and antianxiety agents
Antidepressant and anxiolytic use in FD remains lar-
gely based on anecdotal data. A recent systematic
review addressed antidepressant and antianxiety use in
FD.101 Thirteen studies met the researcher’s inclusion
criteria with 11 demonstrating improvement in dys-
peptic symptoms following treatment. Unfortunately,
significant variability amongst the studies existed
regarding the definition of FD, the measured out-
comes, and the agent evaluated. Meta-analysis could
only be performed on four of the trials (153 total sub-
jects) demonstrating significant benefit of treatment
with antianxiety drugs or antidepressants over placebo
(relative risk: 0.55, 95% CI: 0.36–0.85).
The first high quality randomized trial comparing
the efficacy of a tricyclic antidepressant or TCA (de-
sipramine) to placebo in patients with functional gas-
trointestinal disorders (FGID) was recently published
by Drossman et al.102 Most of the patients had IBS
though some patients with other functional symptoms
were also included. The intention-to-treat (ITT) analy-
sis did not show a statistically significant improvement
in a composite symptom scale between the desipram-
ine and placebo groups (60% vs. 47%, P ¼ 0.13). This
was largely due to the 28% of patients who did not
complete the trial related to adverse drug effects or
non-compliance. When these patients were excluded
from the analysis (per-protocol analysis), desipramine
resulted in a statistically significant benefit compared
with placebo (73% vs. 49%, P ¼ 0.006, NNT ¼ 4).
From this data, we can conclude that many patients
will not tolerate TCAs but those who can tolerate these
medications are likely to experience symptomatic
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benefit. A post hoc analysis from this study suggested
that many of the ‘adverse effects’ attributed to TCA
therapy were present before the initiation of therapy
and thus, may not actually have been caused by the
TCA.103
In a small randomized trial of seven patients with
FD, amitriptyline (50 mg qHS) was found to be more
effective than placebo in improving symptoms.104
Most recently, Otaka et al. demonstrated the efficacy
of amitriptyline in 14 FD patients who initially failed
treatment with famotidine or mosapride reporting a
response rate of 71%.95 Clinical benefit has not been
found to correlate with changes in perception of gas-
tric balloon distention, suggesting that the analgesic
effects of TCAs are likely to be mediated centrally,
perhaps through effects on the cortical processing of
painful visceral sensations.105, 106
When the TCAs are used for FD patients, lower
doses are typically necessary than when treating
depression. For FGID, target doses for the TCAs range
from 10 to 100 mg/day. Higher doses are necessary in
the presence of comorbid psychological conditions like
depression. These drugs are usually dosed in the even-
ing to minimize problems related to their sedative
effects. Patients should also be warned about the pos-
sibility of dry mouth and eyes as well as weight gain
and constipation. Secondary amines, such as nortript-
yline and desipramine may be better tolerated than the
older tertiary amines (amitriptyline, imipramine).
Unlike when used for depression, the clinical benefits
of TCAs for functional disorders are often seen within
2 weeks of initiating therapy.
To date, there have been no randomized, placebo-
controlled trials published in manuscript form which
have evaluated selective serotonin reuptake inhibitors
(SSRIs) for FD. Recent studies suggest that the SSRIs,
paroxetine and sertraline, do not alter the sensation of
gastric balloon distention107, 108 but may alter accom-
modation107 in healthy volunteers. Similarly, there is
no data addressing the physiological or clinical effects
of newer antidepressants, such as venlafaxine or mit-
azapine in patients with FD. Though it is clear that
these agents are of benefit to comorbid depression
and/or anxiety, it remains unclear whether they offer
any benefit to GI symptoms associated with FD in the
absence of concomitant psychiatric conditions.
Because of the social stigma attached to their use and
their narrow therapeutic window, it seems fair to sug-
gest that antidepressants should be reserved for
patients with persistent, moderate to severe symptoms
who have failed to improve with the more conven-
tional forms of medical therapy.
Psychological therapies
A variety of different psychotherapeutic modalities
have been used to treat FGID including insight-orien-
ted psychotherapy, relaxation and stress management
training, cognitive-based behavioural therapy, biofeed-
back and hypnotherapy.109, 110 The best studied of
these techniques is cognitive-behavioural therapy. This
form of psychotherapy is designed to teach patients
how to identify maladaptive behaviours and manage
their responses to emotional and life stresses. Haug et
al. randomized 100 patients with FD to cognitive psy-
chotherapy or no therapy and found that the psycho-
therapy patients experienced significant improvement
in symptoms, such as bloating, epigastric pain and
nausea.111 Mine et al. randomized 198 FD patients to a
combination of medical, psychiatric and psychothera-
peutic treatments vs. medical therapy alone and found
that multimodality therapy afforded significantly
improved outcomes compared with medical therapy
alone.112 Hamilton et al. sought to determine if brief
psychodynamic-interpersonal psychotherapy was
superior to reassurance alone. At the end of the ther-
apy period, FD patients in the psychotherapy group
had significant symptom reduction compared to the
group treated with reassurance alone. A post hoc ana-
lysis at 1 year, removing patients with severe heart-
burn symptoms, indicated a potential benefit for the
psychotherapy group.113 Another recent study in FD
patients found that hypnotherapy yielded a greater
improvement in symptoms as well as quality of life
measures, reduced antidepressant medication and
reduced consultation rates compared with supportive
therapy or medical therapy.110
Though individual trials suggest clinical benefits, a
recent systematic review concluded that there was
insufficient evidence to support the efficacy of
psychological therapies for FD.114 Despite this evi-
dence-based conclusion, it does appear that addressing
life stresses and improving coping mechanisms can be
a useful adjunct to traditional therapies once organic
GI disease has been excluded. Unfortunately, several
factors make the implementation of psychological
therapy challenging in clinical practice. In addition to
overcoming the stigma of referring patients for psy-
chological therapy and the failure of many insurance
plans to cover this form of out-patient treatment, it
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can be difficult to find a mental health professional
with the training and/or willingness to take on
patients with a FGID.
Complementary and alternative medicine
A number of alternative treatment strategies to that of
pharmaceuticals or psychological therapy have been
employed in FD. A recent systematic review reported
that at least 44 different herbal products have been
recommended alone or in combination for the treat-
ment of dyspeptic symptoms.115 This review included
17 RCTs, the largest number of studies having assessed
peppermint and caraway in the treatment of FD. This
analysis revealed symptom improvement in 60–95% of
patients receiving herbal therapy vs. 30–55% in
patients receiving placebo. Unfortunately, the baseline
patient profiles in these trials were not always well
defined and methods of symptom assessment were
variable often relying on scoring systems lacking val-
idation.
A more recent meta-analysis of the combination
herbal remedy, STW 5 (Iberogast), pooled the data of
three RCTs which included 273 FD patients. This meta-
analysis found that STW 5 was superior to placebo at
improving the most bothersome FD symptom reported
by study participants (P ¼ 0.001, odds ratio: 0.22,
95% CI: 0.11–0.41).116
Capsaicin, the active ingredient of red chilli pepper,
has been evaluated in small clinical trials, which have
yielded conflicting results. A RCT assessing capsaicin
in 30 patients with FD demonstrated significant
improvement in overall symptoms, epigastric pain,
fullness and nausea compared with placebo.117 On the
other hand, an earlier placebo-controlled crossover
trial evaluating 11 patients with a primary complaint
of heartburn and associated dyspepsia was unable to
show significant improvements in postprandial dys-
pepsia scores with capsaicin.118 Interestingly, this
study demonstrated worsening in immediate postpran-
dial heartburn when capsaicin was ingested with a
meal.
A RCT assessing artichoke leaf extract in 247
patients with FD demonstrated a significant improve-
ment in both overall symptoms and disease-specific
quality of life compared with placebo.119
Several issues regarding CAM therapies deserve
mention. Available trials almost all suffer from signifi-
cant methodological flaws making the results difficult
to interpret. Further, because these agents are not
regulated as pharmaceuticals, questions regarding
agent purity and potency have been raised. Finally,
though the short-term use appears relatively safe, the
long-term safety of these agents has not been estab-
lished.
Future therapies
A number of agents with antinociceptive properties are
under investigation for the treatment of FD. j-Opioid
receptor agonists that may inhibit somatic and visceral
pain pathways through their effects on peripheral
opioid receptors, are being developed as a possible
treatment for FD. One such agent, fedotozine, yielded
promising preliminary results in the treatment of
FD.120 Unfortunately, data from North America proved
disappointing (unpublished data) and the development
of this drug was halted. Another opioid agonist, asima-
doline, has also shown some possible application for
the treatment of dyspeptic symptoms.121
Other potential targets for emerging agents with
possible effects on visceral sensation include purino-
ceptors, N-methyl-D-aspartate (NMDA) receptors, pro-
tease-activator receptors (PAR)-2, the vanilloid
receptors, sodium-channel receptors and somatostatin
receptors.122 The P2X purinoceptors are ligand-gated
cation-channels located along pH-sensitive vagal and
spinal afferent pathways.123 Although the role of these
receptors in the generation of GI pain remains uncer-
tain, antagonism of the P2X receptor suppressed
inflammation-induced visceral pain in a mouse
model.124
N-Methyl-D-aspartate receptors represent another
class of ligand-mediated ion-channels expressed by
afferent neurones in the enteric nervous system.
NMDA receptors may play a role in visceral hypersen-
sitivity, although the limited available evidence
remains inconclusive. NMDA antagonism was initially
shown to reduce the nociceptive response to colonic
distention in a rat model.125 Paradoxically, the NMDA
antagonist, dextromethorphan, increased the nocicep-
tive response to gastric distention in small study
involving nine healthy adults.126 This response has
been ascribed to dextromethorphan’s low affinity for
the NMDA receptor. Future studies utilizing more
selective NMDA receptor antagonists are eagerly
awaited.
Protease-activator receptors consist of a family of
four large G-protein-coupled receptors. Two of the
receptor types, PAR-1 and PAR-2, have been found
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throughout the GI tract with a number of modulatory
effects on mucosal and smooth muscle function.127
PAR-2 receptors have been identified on gastric mu-
cosal sensory neurones in a rat model.128 Given their
possible roles in the modulation of gastric motor and
sensory function, PAR-2 agonists and antagonists may
be potential candidates for the treatment of FD.
Vanilloid receptors are non-selective cation-chan-
nels located on afferent nerve endings that are activa-
ted by capsaicin, acid and temperature changes. Nerve
fibres containing these vanilloid receptors have been
identified in the mucosal and muscular layers of the
gastric fundus and antrum in several animal mod-
els.129 Such receptors have therefore been postulated
to play a role in gastric nociception.
Proton-gated sodium-channels also known as acid-
sensing ion-channels have been found on primary
afferent neurones. These channels have been suggested
to play a role in the sensory responses of the gastro-
duodenal mucosa to acid exposure.130 Such a hypothe-
sis remains to be tested in asymptomatic volunteers
and dyspeptic patients.
Somatostatin is a neurotransmitter affecting GI
motility, sensation and visceral sensation through six
different G-protein-coupled receptors. The somatosta-
tin analogue, octreotide, has been shown in several
small studies to reduce the sensation of gastric fullness
in healthy patients.131–133 The exact role of somatosta-
tin receptors in FD requires further study.
Acting through alternative pathways, several addi-
tional agents including cholecystokinin (CCK) receptor
antagonists,134 tachykinin receptor antagonists135 and
corticotrophin-releasing factor (CRF) antagonists136
have been postulated to be potentially beneficial for
FD. CCK is a neuropeptide released into the gut in
response to the presence of intraluminal lipids. It is
believed to mediate pain in the gut and known to
inhibit gastric emptying through vagal afferent path-
ways.137, 138 CCK hyperresponsiveness or the interac-
tion of CCK pathways with those of serotonergic
pathways has been postulated to play a role in FD.139
Administration of the synthetic CCK analogue, CCK-8,
has been shown to reproduce dyspeptic symptoms in
90% of a cohort of FD patients and the administration
of a CCK antagonist, loxiglumide, was effective in
controlling dyspeptic symptoms.139 A double-blind,
placebo-controlled trial involving 12 FD patients dem-
onstrated the ability of the CCK antagonist, dexloxig-
lumide, to prevent the dyspeptic symptoms produced
by duodenal lipid infusion, reduce dyspeptic symptoms
experienced by lipid infusion combined with gastric
distention, and reduce sensitivity to distention.46
The tachykinins, substance P, neurokinin A and
neurokinin B, exert their effects through their interac-
tion with tachykinin receptors NK1, NK2 and NK3. The
NK1 antagonist, aprepitant, has demonstrated anti-
emetic properties and is currently approved for the
treatment of chemotherapy-induced nausea and vomit-
ing.140, 141 NK1 antagonism has demonstrated antinoc-
iceptive effects in preclinical animal studies, although
such findings have not been reproduced in humans.142
The precise role of NK3-receptor antagonism in gastro-
vagal functions, gastric motility and nociception
remain largely unknown.143
The hypothalamic-pituitary-adrenal (HPA) axis
serves as the primary endocrine stress system in
humans and provides an important interface between
the brain and the gut-immune system. Activators of the
HPA axis including physical and psychological stress
have been suggested to play a role in FD. A recent study
involving IBS patients found overactivation of the HPA
axis with associated increases in proinflammatory cy-
tokines.144 There is evolving evidence that CRF receptor
antagonists may reduce stress-related alterations in
upper gut function.145 CRF2-receptor antagonism has
been shown to prevent CRF-induced alternations in
gastric motility in a rat model.146 Further, animal stud-
ies have found that CRF1-receptor antagonism abolishes
the gastric ileus that occurs immediately following celi-
otomy and caecal palpation.147 It is hoped that such
preliminary findings may predict clinical applications
for CRF antagonists in the treatment of FD.
Other serotonergic agents are also being investigated
for their possible role in the treatment of FD. Prelimin-
ary work with the 5-HT1 agonist, sumatriptan, has sti-
mulated interest in the development and evaluation of
other 5-HT1 agonists for the treatment of FD.
24, 34 In a
dose ranging study involving women and men with
FD who received placebo or three different doses of
the 5-HT3-receptor antagonist alosetron, only women
who received a dose of 1 mg b.d. achieved statistically
significant improvements in adequate relief of their
dyspeptic symptoms (54% vs. 43%, P < 0.05).148 In the
US, this use of alosetron is restricted to women with
severe IBS that has proven refractory to traditional
treatments because of its association with occasional
severe constipation and rare cases of ischaemic coli-
tis. Other serotonergic agents which may offer bene-
fit to FD include the 5-HT4 antagonists and 5-HT7
agonists.149
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CONCLUSION
The symptoms of FD arise from a heterogeneous group
of pathophysiological abnormalities. The varied symp-
toms that can constitute FD have been acknowledged
in the recently published Rome III criteria.150 The Rome
III criteria for FD offer a general definition meant more
for clinical practice and definitions for two subgroups,
postprandial distress syndrome or epigastric pain syn-
drome, which are intended for clinical research. It is
important to understand that this newly proposed clas-
sification system has not been formally validated in
clinical trials and as such, has no bearing on the cur-
rent management strategies for FD patients. At present,
it is fair to conclude that available therapies are effec-
tive only in subgroups of FD patients. There is evidence
to suggest that eradication of H. pylori infection and
potent antisecretory therapy benefit some patients with
this disorder. Though gastrokinetic drugs have long
been of interest for the treatment of FD, it is becoming
increasingly apparent that the benefits of these drugs
are not solely the consequences of their effects on gas-
tric emptying. Normalization of accommodation and
perhaps most importantly, the co-ordination of func-
tions between the proximal and distal stomach are
likely to be more important than a specific drug’s effect
on gastric emptying. Antidepressants and psychological
therapies appear to offer benefit to appropriately selec-
ted patients. Results from preliminary studies of alter-
native therapies for FD appear promising but should be
considered hypothesis generating rather than definitive
evidence of therapeutic benefit. Numerous agents with
effects on upper GI motor and sensory function are
currently in development and hopefully will expand
the therapeutic toolbox available for this sometimes
challenging group of patients.
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